Detailed Evaluation of Microchimerism
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01094197|
Recruitment Status : Withdrawn (Investigators could not identify subjects who met all inclusion criteria.)
First Posted : March 26, 2010
Last Update Posted : April 12, 2013
|Condition or disease|
|Chimerism Blood Transfusion Wounds and Injuries Hematopoiesis|
Transfusion-associated microchimerism, the persistence of donor white blood cells months or years after transfusion in the recipient, has been observed in approximately 10-15% of transfused trauma patients. Previous studies suggest that the microchimeric cells include multiple immunophenotypes of leukocytes (CD4+, CD8+, CD15+, and CD19+) and that they can persist for decades, features suggestive of hematopoietic engraftment.
In this study, ten subjects known to have long-term microchimerism will undergo either leukapheresis (a blood filtering procedure) or collection of a 500 mL whole blood sample (the amount of a standard blood donation). These samples will then be analyzed to determine whether the microchimeric (donor) cells include hematopoietic stem cells (CD34+) and precursor cells in the red blood cell, white blood cell, and platelet lineages.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Evaluation to Determine Whether Transfusion-associated Microchimerism Involves Engraftment With Hematopoietic Progenitor Cells|
|Study Start Date :||March 2010|
|Estimated Primary Completion Date :||November 2011|
|Estimated Study Completion Date :||November 2011|
Transfused microchimeric subject
Former trauma patient who underwent blood transfusion and has recent evidence of long-term transfusion-associated microchimerism
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01094197
|United States, California|
|University of California, Davis, Medical Center|
|Sacramento, California, United States, 95817|
|Principal Investigator:||Michael P. Busch, MD, PhD||Blood Systems Research Institute|